Validation and development of new dichoptic VR-gaming method to treat childhood amblyopia; Vedea Amblyopia Therapy (VAT)

Validation and development of new dichoptic VR-gaming method to treat childhood amblyopia; Vedea Amblyopia Therapy (VAT) - VR & Amblyopia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON51760

Enrollment

Registered

2022-10-13

Start date

2023-02-22

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amblyopia

Interventions

Use of the VAT for 16 straight weeks for 30 minutes of play per day

Eligibility

Age

2 Years to 11 Years

Inclusion criteria

Inclusion criteria: informed consent aged between 4 and 10 years old wearing full corrected refraction for >=14 weeks diagnosed with an unilateral anisometric, strabismic and/or deprivation amblyopia currently under treatment or starting treatment for unilateral amblyopia access to an Android device equal to or higher than a Samsung Galaxy S8

Exclusion criteria

Exclusion criteria: current treatment with atropine penalisation documented history of severe negative side effects that occur with exposure to VR usage (eg. seizures or epileptic spasms) photosensitivity no developmental delay coexisting ocular pathology or systemic diseases

Design outcomes

Primary

Measure	Time frame
Visual acuity as measured in logmar lines	—

Secondary

Measure	Time frame
Compliance	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)